Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Reloxaliase - Allena Pharmaceuticals

Next Previous
Drug Profile

Reloxaliase - Allena Pharmaceuticals

Alternative Names: ALLN 177; ALTU-237; Oxalate decarboxylase - Allena Pharmaceuticals

Latest Information Update: 21 Jun 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Altus Pharmaceuticals
  • Developer Allena Pharmaceuticals
  • Class Enzymes; Recombinant proteins; Urologics
  • Mechanism of Action Oxalate decarboxylase replacements; Oxalate inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary hyperoxaluria; Hyperoxaluria
  • New Molecular Entity No

Highest Development Phases

  • Phase III Hyperoxaluria
  • Phase II Primary hyperoxaluria

Most Recent Events

  • 19 May 2022 Allena Pharmaceuticals terminates the phase III URIROX-2 trial in Hyperoxaluria in USA, Austria, Belgium, Brazil, Canada, Croatia, France, Germany, Italy, Mexico, Portugal, Romania, Russia, Spain, Switzerland, United Kingdom (PO), based on interim analysis (NCT03847090) (EudraCT2018-000921-29)
  • 04 Jan 2022 Allena Pharmaceuticals announces intention to discuss modifications of a phase III URIROX-2 trial in Hyperoxaluria with the US FDA during Q1 2022
  • 12 Jul 2021 Allena Pharmaceuticals intends to submit revised plan for first interim analysis of phase III URIROX-2 trial to US FDA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top